MetaADEDB 2.0 @ LMMD
ziprasidone
(NZDBKBRIBJLNNT-UHFFFAOYSA-N)
Structure
SMILES
O=C1Nc2c(C1)cc(c(c2)Cl)CCN1CCN(CC1)c1nsc2c1cccc2.Cl
Molecular Formula:
C21H22Cl2N4OS
Molecular Weight:
449.397
Log P:
4.7519
Hydrogen Bond Acceptor:
6
Hydrogen Bond Donor:
2
TPSA:
76.71
CAS Number(s):
122883-93-6
Synonym(s)
1.
ziprasidone
2.
5-(2-(4-(3-benzisothiazolyl)piperazinyl)ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one
3.
CP 88059
4.
CP 88059-01
5.
CP-88,059
6.
CP-88,059-01
7.
CP-88,059-1
8.
Geodon
9.
ziprasidone hydrochloride
10.
ziprasidone hydrochloride, monohydrate
11.
ziprazidone
External Link(s)
MeSHC092292
PubChem Compound219099
67108352
BindingDB50366825
CHEMBLCHEMBL1712
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1Drug ineffectiveFAERS: 53
Canada Vigilance: 1
Canada Vigilance
US FAERS
2AnxietyFAERS: 16US FAERS
3AgitationFAERS: 12US FAERS
4Product substitution issueFAERS: 12US FAERS
5Feeling abnormalFAERS: 9US FAERS
6HeadacheFAERS: 8US FAERS
7TremorFAERS: 8US FAERS
8DizzinessFAERS: 7US FAERS
9MalaiseFAERS: 7US FAERS
10SomnolenceFAERS: 7US FAERS
11TachycardiaFAERS: 7US FAERS
12VomitingFAERS: 7US FAERS
13Blood creatine phosphokinase increasedFAERS: 6US FAERS
14DystoniaFAERS: 6US FAERS
15PainFAERS: 6US FAERS
16Completed SuicideFAERS: 5US FAERS
17FatigueFAERS: 5US FAERS
18Mental status changesFAERS: 5US FAERS
19Neuroleptic Malignant SyndromeFAERS: 5US FAERS
20ParanoiaFAERS: 5US FAERS
21AstheniaFAERS: 4US FAERS
22HypersensitivityFAERS: 4US FAERS
23Mood swingsFAERS: 4US FAERS
24NauseaFAERS: 4US FAERS
25No adverse eventFAERS: 4US FAERS
26PriapismFAERS: 4US FAERS
27Product use in unapproved indicationFAERS: 4US FAERS
28SyncopeFAERS: 4US FAERS
29Accidental exposureFAERS: 3US FAERS
30Activation syndromeFAERS: 3US FAERS
31AkathisiaFAERS: 3US FAERS
32AngerFAERS: 3US FAERS
33Atrioventricular BlockFAERS: 3US FAERS
34Bulimia NervosaFAERS: 3US FAERS
35Cardiac ArrestFAERS: 3US FAERS
36Chest PainFAERS: 3US FAERS
37CryingFAERS: 3US FAERS
38DehydrationFAERS: 3US FAERS
39DeliriumFAERS: 3US FAERS
40Disease recurrenceFAERS: 3US FAERS
41DroolingFAERS: 3US FAERS
42Obsessive-Compulsive DisorderFAERS: 3US FAERS
43PleurothotonusFAERS: 3US FAERS
44Respiratory FailureFAERS: 3US FAERS
45Respiratory muscle weaknessFAERS: 3US FAERS
46RestlessnessFAERS: 3US FAERS
47StressFAERS: 3US FAERS
48Suicide attemptFAERS: 3US FAERS
49Tardive DyskinesiaFAERS: 3US FAERS
50Urinary IncontinenceFAERS: 3US FAERS
51Visual ImpairmentFAERS: 3US FAERS
52Accidental overdoseFAERS: 2US FAERS
53Adverse eventFAERS: 2US FAERS
54AngioedemaFAERS: 2US FAERS
55AstigmatismFAERS: 2US FAERS
56Blood creatinine decreasedFAERS: 2US FAERS
57Blood glucose increasedFAERS: 2US FAERS
58BradycardiaFAERS: 2US FAERS
59CataractFAERS: 2US FAERS
60Cogwheel RigidityFAERS: 2US FAERS
61ColectomyFAERS: 2US FAERS
62DiscomfortFAERS: 2US FAERS
63Drug dispensing errorFAERS: 2US FAERS
64Drug effect incompleteFAERS: 2US FAERS
65Drug exposure during pregnancyFAERS: 2US FAERS
66Drug withdrawal syndromeFAERS: 2US FAERS
67DysgeusiaFAERS: 2US FAERS
68Female Orgasmic DisorderFAERS: 2US FAERS
69Female sexual arousal disorderFAERS: 2US FAERS
70HypomaniaFAERS: 2US FAERS
71HyporeflexiaFAERS: 2US FAERS
72HypotensionFAERS: 2US FAERS
73Middle insomniaFAERS: 2US FAERS
74Muscle RigidityFAERS: 2US FAERS
75Musculoskeletal stiffnessFAERS: 2US FAERS
76MyopiaFAERS: 2US FAERS
77PalpitationsFAERS: 2US FAERS
78PancreatitisFAERS: 2US FAERS
79PolydipsiaFAERS: 2US FAERS
80Product use issueFAERS: 2US FAERS
81Pseudoexfoliation of lens capsuleFAERS: 2US FAERS
82Psychiatric decompensationFAERS: 2US FAERS
83Pulmonary congestionFAERS: 2US FAERS
84Sinus bradycardiaFAERS: 2US FAERS
85TheftFAERS: 2US FAERS
86TorticollisFAERS: 2US FAERS
87UrticariaFAERS: 2US FAERS
88Ventricular FibrillationFAERS: 2US FAERS
89Weight decreasedFAERS: 2US FAERS
90White blood cell count decreasedFAERS: 2US FAERS
91Wrong technique in product usage processFAERS: 2US FAERS
92AcneFAERS: 1US FAERS
93Alanine Aminotransferase IncreasedFAERS: 1US FAERS
94Alcohol abuseFAERS: 1US FAERS
95AlopeciaFAERS: 1US FAERS
96Altered visual depth perceptionFAERS: 1US FAERS
97AmnesiaFAERS: 1US FAERS
98Anaphylactoid ReactionFAERS: 1US FAERS
99Anoxic EncephalopathyFAERS: 1US FAERS
100ArthralgiaFAERS: 1US FAERS
101Aspartate Aminotransferase IncreasedFAERS: 1US FAERS
102Autoimmune thyroiditisFAERS: 1US FAERS
103Autonomic nervous system imbalanceFAERS: 1US FAERS
104Bipolar DisorderFAERS: 1US FAERS
105Blood creatinine increasedFAERS: 1US FAERS
106Blood glucose fluctuationFAERS: 1US FAERS
107Blood immunoglobulin E increasedFAERS: 1US FAERS
108Blood lactate dehydrogenase increasedFAERS: 1US FAERS
109Blood pH decreasedFAERS: 1US FAERS
110Blood triglycerides increasedFAERS: 1US FAERS
111Blood urea increasedFAERS: 1US FAERS
112Breast CystFAERS: 1US FAERS
113Burning sensationFAERS: 1US FAERS
114CardiomegalyFAERS: 1US FAERS
115Cardiovascular insufficiencyFAERS: 1US FAERS
116CellulitisFAERS: 1US FAERS
117Cerebral atrophyFAERS: 1US FAERS
118Cerebrovascular accidentFAERS: 1US FAERS
119Chest discomfortFAERS: 1US FAERS
120ChillsFAERS: 1US FAERS
121Complement factor C3 increasedFAERS: 1US FAERS
122Complement factor C4 increasedFAERS: 1US FAERS
123CystFAERS: 1US FAERS
124Depressed Level of ConsciousnessFAERS: 1US FAERS
125Depressed moodFAERS: 1US FAERS
126Diabetes MellitusFAERS: 1US FAERS
127Diabetic KetoacidosisFAERS: 1US FAERS
128DiplegiaFAERS: 1US FAERS
129DisorientationFAERS: 1US FAERS
130Drug DependenceFAERS: 1US FAERS
131Drug ToleranceFAERS: 1US FAERS
132Drug administration errorFAERS: 1US FAERS
133Drug ineffective for unapproved indicationFAERS: 1US FAERS
134Drug toxicityFAERS: 1US FAERS
135DysarthriaFAERS: 1US FAERS
136DysplasiaFAERS: 1US FAERS
137Ear discomfortFAERS: 1US FAERS
138Electrocardiogram ST segment abnormalFAERS: 1US FAERS
139Electroencephalogram abnormalFAERS: 1US FAERS
140Emotional disorderFAERS: 1US FAERS
141Emotional distressFAERS: 1US FAERS
142Erection increasedFAERS: 1US FAERS
143ErythemaFAERS: 1US FAERS
144Euphoric moodFAERS: 1US FAERS
145Feeling jitteryFAERS: 1US FAERS
146Flat affectFAERS: 1US FAERS
147Flight of ideasFAERS: 1US FAERS
148FolliculitisFAERS: 1US FAERS
149GastritisFAERS: 1US FAERS
150Gaze palsyFAERS: 1US FAERS
151Hallucinations, mixedFAERS: 1US FAERS
152Hepatitis A antibody positiveFAERS: 1US FAERS
153Hypertensive crisisFAERS: 1US FAERS
154HypervigilanceFAERS: 1US FAERS
155Impaired work abilityFAERS: 1US FAERS
156Inappropriate affectFAERS: 1US FAERS
157IncoherentFAERS: 1US FAERS
158Infantile back archingFAERS: 1US FAERS
159Initial insomniaFAERS: 1US FAERS
160Intentional product use issueFAERS: 1US FAERS
161Intentional self-injuryFAERS: 1US FAERS
162Irregular sleep phaseFAERS: 1US FAERS
163Joint injuryFAERS: 1US FAERS
164Joint stiffnessFAERS: 1US FAERS
165Kounis SyndromeFAERS: 1US FAERS
166LacerationFAERS: 1US FAERS
167LethargyFAERS: 1US FAERS
168LeukopeniaFAERS: 1US FAERS
169Limb discomfortFAERS: 1US FAERS
170Lower respiratory tract inflammationFAERS: 1US FAERS
171Macular degenerationFAERS: 1US FAERS
172Medication ErrorFAERS: 1US FAERS
173Memory impairmentFAERS: 1US FAERS
174Mental impairmentFAERS: 1US FAERS
175Muscle SpasticityFAERS: 1US FAERS
176Muscle tightnessFAERS: 1US FAERS
177NasopharyngitisFAERS: 1US FAERS
178Neck PainFAERS: 1US FAERS
179NegativismFAERS: 1US FAERS
180NephrolithiasisFAERS: 1US FAERS
181NervousnessFAERS: 1US FAERS
182NeuralgiaFAERS: 1US FAERS
183Neutrophil count decreasedFAERS: 1US FAERS
184NoduleFAERS: 1US FAERS
185Oculogyric crisisFAERS: 1US FAERS
186Oropharyngeal painFAERS: 1US FAERS
187OverdoseFAERS: 1US FAERS
188PCO2 increasedFAERS: 1US FAERS
189Pacemaker generated rhythmFAERS: 1US FAERS
190PancreatectomyFAERS: 1US FAERS
191Parkinsonian rest tremorFAERS: 1US FAERS
192Pathological fractureFAERS: 1US FAERS
193Personality ChangeFAERS: 1US FAERS
194PoisoningFAERS: 1US FAERS
195PregnancyFAERS: 1US FAERS
196PresyncopeFAERS: 1US FAERS
197Product packaging issueFAERS: 1US FAERS
198Product physical issueFAERS: 1US FAERS
199Product size issueFAERS: 1US FAERS
200Product taste abnormalFAERS: 1US FAERS
201PruritusFAERS: 1
Canada Vigilance: 1
Canada Vigilance
US FAERS
202Psychiatric symptomFAERS: 1US FAERS
203PurpuraFAERS: 1US FAERS
204Rash erythematousFAERS: 1US FAERS
205Rebound effectFAERS: 1US FAERS
206Restless Legs SyndromeFAERS: 1US FAERS
207Retained products of conceptionFAERS: 1US FAERS
208RhabdomyolysisFAERS: 1US FAERS
209RhinitisFAERS: 1US FAERS
210SchizophreniaFAERS: 1US FAERS
211Serotonin SyndromeFAERS: 1US FAERS
212ShockFAERS: 1US FAERS
213Sleep ParalysisFAERS: 1US FAERS
214Sleep-related eating disorderFAERS: 1US FAERS
215Slow response to stimuliFAERS: 1US FAERS
216SluggishnessFAERS: 1US FAERS
217SnoringFAERS: 1US FAERS
218SomnambulismFAERS: 1US FAERS
219StrabismusFAERS: 1US FAERS
220Suspected product quality issueFAERS: 1US FAERS
221Therapy non-responderFAERS: 1US FAERS
222Throat irritationFAERS: 1US FAERS
223ThrombocytopeniaFAERS: 1US FAERS
224TinnitusFAERS: 1US FAERS
225ToothacheFAERS: 1US FAERS
226Type III immune complex mediated reactionFAERS: 1US FAERS
227Urinary tract infectionFAERS: 1US FAERS
228Urine output increasedFAERS: 1US FAERS
229WheezingFAERS: 1US FAERS
230Wrong technique in drug usage processFAERS: 1US FAERS
231YawningFAERS: 1US FAERS
232furuncleFAERS: 1US FAERS
233nervous system disorderFAERS: 1US FAERS
234AnorgasmiaCanada Vigilance: 1Canada Vigilance
235Disturbance in sexual arousalCanada Vigilance: 1Canada Vigilance
236Lichen PlanusCanada Vigilance: 1Canada Vigilance
237Myocardial InfarctionCanada Vigilance: 1Canada Vigilance
238Sexual DysfunctionCanada Vigilance: 1Canada Vigilance
239Skin lesionCanada Vigilance: 1Canada Vigilance
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120234

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.